Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE*3Leiden.CETP mice. Mice receive...

Full description

Bibliographic Details
Main Authors: Susan Kühnast, José W.A. van der Hoorn, Elsbet J. Pieterman, Anita M. van den Hoek, William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J. Wouter Jukema, Hans M.G. Princen
Format: Article
Language:English
Published: Elsevier 2014-10-01
Series:Journal of Lipid Research
Subjects:
APOE*3Leiden.CETP mice
proprotein convertase subtilisin/kexin type 9
atorvastatin
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520350148

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520350148

Similar Items